Biotechnology - Protein Engineering & Expression Platforms
Strategic Profile
Dyadic offers the Dapibus Protein Production Platform (a proprietary expression system for non-animal proteins and enzymes) and C1 Protein Production Platform (a thermophilic fungal platform for large-scale protein production). The company is executing a strategy to transition into a commercially driven organization by broadening market access, introducing new products, and deepening its partner network across life sciences, food and nutrition, and bioindustrial sectors.
Cyborg Score Rationale
Q1 2026 revenue grew 182% year-over-year to $1.1 million driven by product launches and expanded partnerships; loss from operations improved, and commercial momentum is building across life sciences, food, and industrial segments. However, the company remains unprofitable with negative operating income.
Top Insights
Q1 2026 (May 2026 report) showed 182% year-over-year revenue growth to $1.1 million with improved operating losses and cash runway extending into Q2 2027.
Major commercial launches in March 2026 include AlbuFree™ DX with Proliant Health & Biologicals, animal-origin-free DNase I with Fermbox Bio, OEM distribution agreement with IBT Bioservices, and development agreement with BRIG Bio.
Received initial purchase orders for recombinant bovine transferrin from cultivated meat industry customers; strategic partnerships and direct sales are driving early revenues with significant growth expected from late 2026.
Rebranded to Dyadic Applied BioSolutions in mid-2025 to emphasize transition to commercially focused biotechnology.
Named Competitors
Mammalian cell expression platforms — Large-scale protein production services
Insect cell expression platforms — Protein expression and bioprocess services
Cultivated meat media ingredients — Animal-free protein ingredients for alternative proteins
Recent Developments
(May 2026) Q1 2026 earnings: revenue grew 182% YoY to $1.1M; cash runway extends to Q2 2027
(March 2026) Commercial launch of AlbuFree™ DX with Proliant; expanded Fermbox partnership with DNase I launch; OEM agreement with IBT Bioservices; development agreement with BRIG Bio
(June 2025) Joe Hazelton appointed President; company rebranded to Dyadic Applied BioSolutions mid-2025
Open the full interactive DYADIC INTERNATIONAL INC report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.